The following table lists the companies in the 2014 Executive Peer Group, along with Isis’ rankings among
these companies, based on market capitalization, and financial data reported by each company for the most
recently-reported fiscal year at the time the Compensation Committee selected the Executive Peer Group, in June
2014.
Company (ticker)
Annual Revenues
(inmillions)
Market
Capitalization
(inmillions)
Stage of Lead
Drug
Accorda Therapeutics (ACOR). . . . . . . . . . . . . . . . . . . . . . .
$ 336.4
$1,589.2 Market
Akorn (AKRX) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 317.7
$2,094.5 Market
Alkermes (ALKS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 575.6
$6,400.5 Market
AlnylamPharmaceuticals (ALNY). . . . . . . . . . . . . . . . . . . .
$ 47.2
$4,194.2 Phase III
Arena Pharmaceuticals (ARNA). . . . . . . . . . . . . . . . . . . . . .
$ 81.4
$1,462.5 Market
Ariad Pharmaceuticals (ARIA). . . . . . . . . . . . . . . . . . . . . . .
$ 45.6
$1,501.8 Market
AuxiliumPharmaceuticals (AUXL) . . . . . . . . . . . . . . . . . . .
$ 400.7
$1,406.3 Market
Exelixis (EXEL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 31.3
$ 718.1 Market
Halozyme Therapeutics (HALO) . . . . . . . . . . . . . . . . . . . . .
$ 54.8
$1,505.4 Market
ImmunoGen (IMGN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 35.5
$1,255.1 Market
Incyte Corporation (INCY). . . . . . . . . . . . . . . . . . . . . . . . . .
$ 354.9
$9,015.1 Market
InterMune (ITMN) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 70.3
$3,307.2 Phase III
Jazz Pharmaceuticals (JAZZ) . . . . . . . . . . . . . . . . . . . . . . . .
$ 872.4
$8,137.7 Market
Lexicon Pharmaceuticals (LXRX) . . . . . . . . . . . . . . . . . . . .
$ 2.2
$ 930.0 Phase III
MannKind (MNKD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 0.0
$2,636.7 Phase III
Medivation (MDVN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 272.9
$4,980.0 Market
Momenta Pharmaceuticals (MNTA) . . . . . . . . . . . . . . . . . . .
$ 35.5
$ 606.1 Market
Nektar Therapeutics (NKTR) . . . . . . . . . . . . . . . . . . . . . . . .
$ 148.9
$1,590.7 Market
NPS Pharmaceuticals (NPSP). . . . . . . . . . . . . . . . . . . . . . . .
$ 155.6
$3,104.1 Market
Pacira (PCRX). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 85.6
$2,326.9 Market
Pharmacyclics (PCYC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 260.2
$7,644.9 Market
Seattle Genetics (SGEN). . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 269.3
$5,400.2 Market
TheMedicines Company (MDCO) . . . . . . . . . . . . . . . . . . .
$ 687.9
$1,620.8 Market
Theravance (THRX) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$ 4.8
$3,437.7 Market
United Therapeutics (UTHR) . . . . . . . . . . . . . . . . . . . . . . . .
$1,117.0
$4,874.6 Market
Isis Pharmaceuticals, Inc. (ISIS). . . . . . . . . . . . . . . . . . . . . .
$ 147.3
$4,958.2 Market
Isis’ Ranking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14
7
NA
Isis’ Percentile Rank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46%
75% NA
The table below compares total cash compensation and the total direct compensation of our NEO’s against
that of the 50
th
percentile of the Executive Peer Group.
2014 Total Cash Compensation
(in thousands)
2014 Total Direct Compensation
(in thousands)
Name
NEO
50
th
Percentile of
Executive Peer
Group
NEO
50
th
Percentile
of Executive
Peer Group
Stanley T. Crooke. . . . . . . . . . . . . . . . . . .
$1,488,488 $1,327,900 $6,228,143 $4,126,200
Elizabeth L. Hougen. . . . . . . . . . . . . . . . .
$ 584,600 $ 585,100 $1,741,542 $1,425,900
B. Lynne Parshall . . . . . . . . . . . . . . . . . . .
$1,130,924 $ 855,100 $3,232,043 $2,864,500
Richard Geary. . . . . . . . . . . . . . . . . . . . . .
$ 636,066 $ 372,300 $1,785,888 $ 575,200
Brett Monia. . . . . . . . . . . . . . . . . . . . . . . .
$ 630,139
* $1,787,115
*
* Due to the unique and complex nature of Dr. Monia’s position at Isis, the outside compensation consultant
advised the Compensation Committee that there were no appropriate comparable positions within the
Executive Peer Group.
101
